Tolerability of 2.5% Lidocaine/Prilocaine Hydrogel in Children Undergoing Cryotherapy for Molluscum Contagiosum

The tolerability of a 2.5% lidocaine/prilocaine hydrogel (Nanorap, Biolab Indústria Farmacêutica Ltd., Sao Paulo, Brazil) was evaluated in 20 children ages 2 to 11 years undergoing cryotherapy for molluscum contagiosum (MC). The product was well tolerated, with only two children presenting with ecze...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2016-05, Vol.33 (3), p.e214-e215
Main Authors: Gobbato, André A.M., Babadópulos, Tainah, Gobbato, Cintia A.R.S., Moreno, Ronilson A., Gagliano-Jucá, Thiago, De Nucci, Gilberto
Format: Article
Language:English
Subjects:
Anesthetics, Local - therapeutic use
Child
Child, Preschool
Cryotherapy - adverse effects
Cryotherapy - methods
Drug Combinations
Drug Tolerance
Female
Humans
Hydrogel, Polyethylene Glycol Dimethacrylate
Lidocaine - therapeutic use
Male
Molluscum Contagiosum - diagnosis
Molluscum Contagiosum - therapy
Pain - etiology
Pain - prevention & control
Pain Measurement
Prilocaine - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The tolerability of a 2.5% lidocaine/prilocaine hydrogel (Nanorap, Biolab Indústria Farmacêutica Ltd., Sao Paulo, Brazil) was evaluated in 20 children ages 2 to 11 years undergoing cryotherapy for molluscum contagiosum (MC). The product was well tolerated, with only two children presenting with eczema at the application site. These adverse reactions were considered unlikely to be related to the test product, because a patch test was negative in one of the individuals and the other event occurred in only one of the two treated areas. Nanorap is an efficacious and well‐tolerated option for topical anesthesia in children undergoing cryotherapy for MC.
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.12842